Recent

% | $
Quotes you view appear here for quick access.

Regeneron Pharmaceuticals, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • Networthdev Networthdev May 23, 1999 5:10 PM Flag

    Annual Meeting

    Axokine for Type II diabetes in obese patients
    and uncomplicated obesity, in trials, NT3 trials,
    three different BDNF trials (Regeneron,
    Amgen-Regeneron, & Sumitomo), at least one Cytokine trap to be in
    the clinic in 2000, significant angiogenesis
    research, and more. Add to this, a solid balance sheet, P&G
    support, Amgen support, long term agreement/relationship
    to manufacture intermediate for Merck, Roy Vagelos
    (former Chairman of the Board and Chief Executive Officer
    of Merck & Co.) at the helm, 1998 revenues of over
    45 million and a market cap of only about 180
    million.

    Roy how about the next time you go to a Prudential
    board of directors meeting, you ask if Ralph Acompora
    would like to come visit and have a jelly donut or
    maybe a cream filled. I'm not sure how much Ralph
    really knows, but people seem to like his opinion and he
    looks like he likes donuts. Analyst are a little slow
    so a donut or two might be helpful/necessary. It
    would seem that some coverage might not be too far down
    the road.

 
REGN
402.97+2.72(+0.68%)Aug 26 4:00 PMEDT